Lumos Pharma — NewLink Genetics — Q2 2016 Earnings Presentation
10 slides from Lumos Pharma's earnings presentation, Jul 29, 2016
Slide 1: Second Quarter 2016 Financial Results
NewLink Genetics Corporation Nasdaq: NLNK July 29, 2016 Second Quarter 2016 Financial Results
Slide 2: Agenda
Agenda 2 Introduction Jack Henneman, Executive Vice President & CFO 2016 Ongoing Priorities Charles J. Link, Jr., M.D., Chairman, CEO & CSO Clinical Updates Nicholas N. Vahanian, M.D., President & CMO Restructuring & Second Quarter 2016 Financial Results Mr. Henneman
Slide 3: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements of NewLink Genetics that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation are forward-looking statements, w
Slide 4: NewLink Genetics: Building a Leading Immuno-Oncology Company
4 Oncology Focused Pipeline Two IDO pathway inhibitors in clinical development (indoximod and GDC-0919) Research collaboration with Genentech for IDO and TDO inhibitors Small molecule program focused on additional immuno-oncology targets Strong Scientific and Business Leadership Executing on
Slide 5: Ongoing Priorities
5 Progress and accelerate the development of indoximod Continue Genentech and Merck alliances Advance PTEN and Zika Evaluate external opportunities for pipeline expansion Ongoing Priorities
Slide 6: NewLink Genetics' IDO Pathway Inhibitors
NewLink Genetics’ IDO Pathway Inhibitors 6 AGENT INDICATION DESIGN STATUS Indoximod Breast cancer (metastatic) Indoximod + taxane; randomized Pancreatic cancer (metastatic) Indoximod + gemcitabine and nab-paclitaxel Glioblastoma multiforme Indoximod + temozolomide Melanoma (advanced) Indoximod + ipi
Slide 7: 2016-2018 Cash Conservation Initiatives
7 Conserve cash Wind-down HyperAcute Cellular Immunotherapy trials and manufacturing activities Carefully planned company-wide headcount reductions to ~130 Consolidate/scale-back facilities footprint Eliminate commercialization spending Capital spending reduced to primarily supporting R&D
Slide 8: "Before and After" Summary
8 Substantial cash runway Before After Headcount ~230 ~130 Facilities 133K sq ft 66K sq ft Annual Lease Cost $1.4mm $0.8mm Clinical Trials 19 (finish 15 existing, 4 new) 4-8 Quarterly Negative Cash- flow ~$20mm ~$12 mm Quarters of Cash ~8 10+ “Before and After” Summary
Slide 9: Second Quarter 2016 Financial Results
Second Quarter 2016 Financial Results 9 Jack Henneman, EVP and Chief Financial Officer Strong Capital Position Stable and reliable cash position - $160.5M at Q2 2016 / $197.8M at YE 2015 Goal and expectation to finish 2016 with two years of cash-on-hand Multiple Value Drivers Capacity for Increm
Slide 10: Brewin
Brewin A